Treasury Proposes $50,000 Threshold for US Investment Curbs on China Tech

US investments in Chinese technology exceeding $50,000 would face new reporting requirements or outright prohibitions under a Treasury Department proposal announced October 22. The rules cover advanced semiconductors, artificial intelligence, quantum computing, high-performance computing, hypersonic systems and — for the first time at this scope — biotechnology.

Treasury Secretary Scott Bessent said the rules would prevent adversaries from using American capital to develop technologies that threaten US security while giving investors greater clarity. That clarity, however, depends on definitions the proposal leaves to final regulations.

The proposal implements the Comprehensive Outbound Investment National Security Act, passed by Congress in 2025 as part of the fiscal 2026 National Defense Authorization Act. It expands the Outbound Investment Security Program that former President Joe Biden established in 2023. The restricted-country list extends beyond China to include Russia, Iran and North Korea. Notably, Treasury's AI provisions use the term "super intelligence" — language that will require interpretation before anyone knows which systems fall inside the fence.

Why is biotechnology the flashpoint?

The biotechnology provisions reach certain gene- and cell-modifying treatments, immunotherapies and brain-computer interface technologies. That breadth raises questions about how national security rules will affect drug development and research partnerships.

Craig Singleton, a senior fellow at the Foundation for Defense of Democracies, told the Financial Times that biotechnology was particularly significant because the same innovations can advance medicine while supporting military capabilities or creating supply-chain dependencies. The dual-use problem is the core issue: the tools are identical, only the application differs.

The Biotechnology Innovation Organization warned that overly broad restrictions could create uncertainty for researchers and investors while weakening US competitiveness. The industry's own trade group, in other words, is not disputing the security rationale — only the drafting.

One carve-out matters for pharmaceutical companies. According to the Financial Times, cash-based licensing deals that do not involve an equity investment would be exempt, potentially preserving arrangements through which American drugmakers license medicines developed in China. The distinction is consequential: licensing intellectual property and acquiring an ownership stake create different investment and compliance considerations.

How has China responded?

China's Ministry of Commerce condemned the proposal as discriminatory and said it ran counter to agreements between the countries' leaders. Beijing reserved the right to take corresponding measures.

The dispute adds pressure to US-China economic relations despite recent efforts to extend a trade truce. Washington now treats investment, exports and access to advanced computing as connected national security concerns rather than separate policy files.

What will compliance cost?

The Associated Press reported that the rules would apply to investments exceeding $50,000 and exclude many financial investments, including stock purchases. The exact scope will depend on the final regulations — a caveat that applies to nearly every provision in the proposal.

Treasury has already shown it will enforce the existing program. The department fined a US-based company $200,000 for failing to report a subsidiary's $92,500 investment in a Chinese AI and robotics company, the Associated Press reported. A fine of $200,000 on an unreported deal worth less than half that amount signals the reporting obligation itself carries risk, not just prohibited transactions.

For US investors, venture capital firms and technology companies, the proposal could complicate investments in Chinese technology businesses. Firms may need stronger screening procedures to determine whether a target company, its activities or a planned transaction falls within the restrictions. That diligence burden arrives before anyone knows whether a deal is permitted — companies could face compliance questions at the investigation stage.

The consequences extend to research. Companies that depend on Chinese partners for early-stage drug research may find the biotechnology provisions particularly difficult. Clearer rules could reduce uncertainty, but overly expansive definitions could also discourage legitimate collaborations. Businesses could face higher legal costs, longer deal reviews and fewer options for funding research partnerships.

What happens next?

Treasury will accept public comments before issuing final regulations, which will establish the program's effective date. The comment period is where the biotechnology industry, investors and research institutions will press their case.

The central question is how Treasury defines covered technologies and transactions. Rules that are too narrow could leave security risks unaddressed; rules that are too broad could discourage legitimate research and investment. Public comments will help determine where that line falls before the regulations take effect.

For ordinary users, the effects are likely indirect: restrictions on investment could influence which technologies receive funding and how quickly new medicines, computing systems or AI products reach the market. The proposal does not establish that consumer products or services will be directly restricted.

Until Treasury finalizes the definitions, every dollar above $50,000 into a covered Chinese technology sector sits in a gray zone — and the burden of proving otherwise falls on the investor.